Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | RAF1 | P04049 | 10/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.84 |
| ▸ | BRAF | P15056 | 3/20 | 0.84 |
| ▸ | RET | P07949 | 3/20 | 0.84 |
| ▸ | ARAF | P10398 | 2/20 | 0.84 |
| ▸ | GSK3B | P49841 | 2/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.84 |
| ▸ | ABL1 | P00519 | 2/20 | 0.84 |
| ▸ | HTR1A | P08908 | 2/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.84 |
| ▸ | KIT | P10721 | 2/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.84 |
| ▸ | FLT1 | P17948 | 2/20 | 0.84 |
| ▸ | MAOA | P21397 | 2/20 | 0.84 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.84 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL1533981 | 0.92 | RAF1 (0.98) | KDRRAF1PDGFRBBRAFRET | |
| Sorafenib SCHEMBL29349634 | 0.91 | RAF1 (1.00) | KDRRAF1PDGFRBBRAFRET | |
| Sorafenib SCHEMBL14739751 | 0.91 | RAF1 (1.00) | KDRRAF1PDGFRBBRAFRET | |
| SCHEMBL3407760 | 0.91 | KDR (0.84) | KDRRAF1PDGFRBBRAFRET | |
| Sorafenib SCHEMBL8218 | 0.91 | RAF1 (1.00) | KDRRAF1PDGFRBBRAFRET | |
| SCHEMBL22627130 | 0.91 | RAF1 (0.85) | KDRRAF1PDGFRBBRAFRET | |
| SCHEMBL24535359 | 0.90 | RAF1 (0.84) | KDRRAF1PDGFRBBRAFRET | |
| Sorafenib SCHEMBL1896610 | 0.90 | RAF1 (0.98) | KDRRAF1PDGFRBBRAFRET | |
| SCHEMBL22336541 | 0.90 | RAF1 (0.84) | KDRRAF1PDGFRBBRAFRET | |
| Sorafenib SCHEMBL18863920 | 0.90 | RAF1 (0.98) | KDRRAF1PDGFRBBRAFRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008115263-A2 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | KDR 2667/4885RAF1 925/4885PDGFRB 1790/4885 |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | KDR 1151/4885RAF1 3755/4885PDGFRB 1422/4885 |
| US-20080234332-A1 | RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | BRAF, RAF1, BAZ2B | KDR 1295/4885RAF1 2/4885PDGFRB 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.